How Melanoma Prepares Lymph Nodes for Metastases
Weill Cornell Medicine cancer researchers uncover protein released in exosomes secreted by melanoma cells that leads to lymphangiogenesis.
Promising Treatment Emerges for Recurrent Glioblastoma
Columbia neuro-oncologist leads international phase 2 trial of selinexor, the first of a new class of anticancer drugs.
From COVID Screening to Cancer Outcomes: Scientific Investigations Address COVID-19 and Cancer
Oncologists and other specialists at NewYork-Presbyterian Hospital continue to contribute their expertise and resources to scientific investigations of COVID-19 and its implications for oncology care.
Cancer and Autoimmune Disease: Investigating the Double Duty of T Cells
Research by Adam Mor, MD, PhD, a rheumatologist and molecular immunologist at NewYork-Presbyterian/Columbia University Irving Medical Center, focuses on the function of T lymphocytes in autoimmune disease and cancer
Cardio-Oncology: Staying Ahead of Cancer Care and Its Cardiovascular Consequences
In the rapidly evolving field of cardio-oncology, NewYork-Presbyterian Hospital is making its mark with dedicated programs led by cardiology faculty at Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine.
Gastroenterology & Oncology
Novel Perspectives on Pancreatic Cancer
Comprehensive medical and surgical oncology programs for pancreatic cancer at NYP complement exhaustive research underway by Columbia and Weill Cornell faculty in the basic, translational, and clinical arenas. Their goal is to identify new treatment approaches that defy the odds for surviving this devastating disease.
Urology & Oncology
Bladder Cancer: Therapeutic Trio Offers Potential Alternative to Radical Cystectomy
Patients with Bacillus Calmette-Guerin (BCG)-unresponsive bladder cancer remain a challenging patient population to treat. Radical cystectomy continues as the oncologic gold standard treatment in patients at high risk of recurrence after BCG failure in non-muscle-invasive bladder cancer.
Manuel Hidalgo, MD, PhD: A Pioneer in Pancreatic Cancer
For more than two decades, Dr. Manuel Hidalgo has pursued laboratory and clinical research with a major focus on drug development in pancreatic cancer.
Page1 of 4